Search clinical trials for: Antidiuretic Agents

Total 187780 results

University of Chicago

Completed

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients (TOLVAD)

Heart Failure | Heart Assist Device | Hyponatremic

United States
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Brigham and Women's Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

The Role of Vasopressin Antagonism on Renal Sodium Handling

Healthy
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

Heart Failure With Hyponatremia

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Hyponatremia
University of Florida
Otsuka America Pharmaceutical

Completed

Tolvaptan for Ascites in Cirrhotic Patients

Cirrhosis | Ascites

United States
Cumberland Pharmaceuticals

Completed

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia | Euvolemia | Hypervolemia

Israel, United States, India
Sanofi

Completed

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites (Hypo~CAT)

Liver Cirrhosis | Ascites

United States, France, Romania, Germany, Italy, Spain, Belgium, Czech Republic, Argentina, Croatia, Hungary, Canada, Australia
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Sanofi

Completed

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) (CATS)

Liver Cirrhosis | Ascites

United States, France, Brazil, Poland, Romania, Russian Federation, Italy, Netherlands, Portugal, Sweden, Belgium, Argentina, Croatia, Denmark, Hungary, Israel, Spain, Chile, Canada, United Kingdom, Australia
Otsuka Beijing Research Institute

Completed

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

Ascites | Hepatic Cirrhosis

China
Hoffmann-La Roche

Withdrawn

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

Acute Ischemic Stroke

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites (ECF)

Hyponatremia and Extracellular Fluid in Cirrhotic

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Belgium, Spain, United States, United Kingdom, Italy, Germany, Czechia, Romania
Jesse Corry

Completed

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Stroke | Cerebral Hemorrhage | Intracerebral Hemorrhage | Cerebral Edema

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
Sanofi

Terminated

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (SPARe-1)

Liver Cirrhosis | Ascites

France, Canada, Romania, Australia, Germany, Italy, Portugal, Spain, Bulgaria, Malaysia, Serbia, Singapore, Taiwan, Belgium, Czech Republic, Croatia, Hungary, Israel, United Kingdom, Korea, Republic of, South Africa, United States, ... and more
Cumberland Pharmaceuticals

Completed

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, India
Cumberland Pharmaceuticals
Parke-Davis

Completed

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Poland, United Kingdom, Germany, Spain, Belgium, France, Netherlands, Italy, Finland
Cumberland Pharmaceuticals

Completed

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

South Africa, United States, Israel
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Jiangsu HengRui Medicine Co., Ltd.
Beijing Friendship Hospital; Beijing 302 Hospital; Beijing Anzhen Hospital

Unknown

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Non-hypovolemic Non-acute Hyponatremia

China
Albert Einstein Healthcare Network
Astellas Pharma Inc

Withdrawn

Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

Heart Failure
University of Electronic Science and Technology...

Completed

Differential Effects of Vasopressin and Oxytocin on Attention Control

Healthy

China
University of Nottingham
National Institute for Health Research, United Kingdom

Completed

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage (DASH)

Stroke, Acute

United Kingdom
Ferring Pharmaceuticals

Completed

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients (COMFORT)

Nocturia

United States, Canada
Ferring Pharmaceuticals

Completed

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Nocturia

United States, Canada
National Center for Research Resources (NCRR)
Northwestern University

Completed

Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

Diabetes Insipidus | Diabetes Insipidus, Neurohypophyseal

United States
Sohag University

Recruiting

Value of Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital

Febrile Seizure

Egypt
Asan Medical Center

Completed

AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA

Out-of-Hospital Cardiac Arrest

Korea, Republic of
Medical College of Wisconsin

Completed

Early Use of Vasopressin in Post-Fontan Management (VAMP)

Congenital Heart Disease | Single-ventricle | Circulatory Perfusion Disorder

United States
Gia Dinh People Hospital
Otsuka Pharmaceutical Vietnam

Recruiting

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF)

Acute Heart Failure

Vietnam
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
Hospital Clinic of Barcelona
Instituto de Salud Carlos III; Institut d'Investigacions Biomèdiques August...

Unknown

Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes (OCTAUS-T2D)

Arteriosclerosis | Type 2 Diabetes Mellitus | Diabetic Retinopathy | Carotid Atherosclerosis | Microangiopathy

Spain
University of Aarhus
The Danish Diabetes Association

Completed

Optimized Glycemic Control in Heart Failure Patients With DM2:"Effect on Left Ventricular Function and Skeletal Muscle" (HFDM)

Heart Failure | Type 2 Diabetes

Denmark
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Cumberland Pharmaceuticals

Completed

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

Chronic Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients (INSIGHT)

Hyponatremia

United States
Sanofi

Completed

Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Hyponatremia | Syndrome of Inappropriate ADH (SIADH) Secretion

France, Germany, Belgium, Hungary
Polderman, Kees, H., MD, PhD
University of Pittsburgh

Terminated

Tolvaptan for Patients With Acute Neurological Injuries

Hyponatremia | SIADH

United States
Cumberland Pharmaceuticals

Terminated

Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF) (CONVERT-H)

Acute Decompensated Heart Failure | Hyponatremia

India
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Beijing Research Institute

Completed

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Ascites | Hepatic Cirrhosis

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Heart Failure, Congestive

United States, Romania
Band Therapeutics

Completed

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

Intracranial Arteriosclerosis | Cerebrovascular Stroke | Large-Artery Atherosclerosis (Embolus/Thrombosis)

Austria

Search clinical trials for: Antidiuretic Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations